Io Biotech, INC Form 4 insider transactions

IO Biotech, Inc. Director David V. Smith was granted 35,144 stock options with an exercise price of $1.50, vesting on June 5, 2026.

IO Biotech, Inc. Director Heidi Hunter was granted 35,144 stock options with an exercise price of $1.50, vesting on June 5, 2026.

IO Biotech, Inc. Director Peter Hirth was granted 35,144 stock options with an exercise price of $1.50, vesting in June 2026.

IO Biotech, Inc. Director Kathleen Sereda Glaub has been granted 35,144 stock options with an exercise price of $1.50, which are set to vest on June 5, 2026.

IO Biotech, Inc. Director Christian E. Elling was granted 35,144 stock options with an exercise price of $1.50, vesting on June 5, 2026.

IO Biotech, Inc. Director Helen Louise Collins was granted 35,144 stock options with an exercise price of $1.50, aligning her interests with the company's long-term performance.

IO Biotech, Inc. Director Heidi Hunter has acquired 15,000 shares of the company's common stock through a pre-planned transaction, signaling increased insider confidence.

IO Biotech's CEO, Mai-Britt Zocca, reports the acquisition of 580,000 stock options exercisable for common stock.

Amy Sullivan, CFO of IO Biotech, Inc., reports the acquisition of stock options.

Devin Whittemore Smith, General Counsel of IO Biotech, Inc., acquired 140,000 stock options on April 2, 2025.

Brian Burkavage, Chief Accounting Officer of IO Biotech, Inc., reports the acquisition of stock options.

Qasim Iftikhar Ahmad, Chief Medical Officer of IO Biotech, Inc., reports the acquisition of 215,000 stock options.

IO Biotech's Chief Medical Officer, Qasim Iftikhar Ahmad, acquired 31,350 shares of common stock at a price of $0.847 per share on December 23, 2024.

IO Biotech's CEO, Mai-Britt Zocca, purchased 12,500 shares of common stock at $0.8096 per share on December 23, 2024.

IO Biotech's Chief Financial Officer, Amy Sullivan, purchased 10,250 shares of common stock at a weighted average price of $0.8276 per share.

IO Biotech's General Counsel, Devin Whittemore Smith, acquired 12,000 shares of common stock at $0.81 per share on December 23, 2024.

Novo Holdings A/S, a 10% owner of IO Biotech, Inc., sold shares of common stock in two transactions on July 25 and July 26, 2024.

Director David V. Smith acquired 45,642 stock options in IO Biotech, Inc. on June 6, 2024.

Director Heidi Hunter acquired stock options in IO Biotech, Inc. on June 6, 2024.

Director Peter Hirth acquired 45,642 stock options in IO Biotech, Inc. on June 6, 2024.

Kathleen Sereda Glaub, a director of IO Biotech, Inc., acquired 45,642 stock options on June 6, 2024, exercisable at $1.25.

Christian Elling, a director at IO Biotech, acquired stock options for 45,642 shares of common stock on June 6, 2024.

Helen Louise Collins, a director at IO Biotech, Inc., acquired 45,642 stock options on June 6, 2024, exercisable at $1.25 per share.

Novo Holdings A/S, a major shareholder of IO Biotech, Inc., sold 658,809 shares of common stock at a price of $1.2181 per share on May 10, 2024.

IO Biotech's CEO, Mai-Britt Zocca, acquired 750,000 stock options on March 15, 2024, according to a Form 4 filing.

Amy Sullivan, CFO of IO Biotech, Inc., reports the acquisition of stock options.

Devin Whittemore Smith, General Counsel of IO Biotech, acquired stock options for 185,000 shares of common stock on March 15, 2024.

Brian Burkavage, Chief Accounting Officer of IO Biotech, Inc., acquired 50,000 stock options on March 15, 2024, according to a Form 4 filing with the SEC.

Qasim Iftikhar Ahmad, Chief Medical Officer of IO Biotech, Inc., acquired 280,000 stock options on March 15, 2024.